Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1999;33:190-194

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dubey, R. K.
Right arrow Articles by Jackson, E. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dubey, R. K.
Right arrow Articles by Jackson, E. K.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*(L)-PROLINE

(Hypertension. 1999;33:190-194.)
© 1999 American Heart Association, Inc.


Scientific Contribution

Adenosine Inhibits Collagen and Total Protein Synthesis in Vascular Smooth Muscle Cells

Presented at the Annual American Heart Association Meeting for Council for High Blood Pressure, Philadelphia, September 1998, and published in abstract form (Hypertension, 1998).

Raghvendra K. Dubey; Delbert G. Gillespie; Edwin K. Jackson

Correspondence to Dr Raghvendra K. Dubey, Center for Clinical Pharmacology, 623 Scaife Hall, 200 Lothrop Street, University of Pittsburgh Medical Center, Pittsburgh, PA 15213-2582, USA. E-mail dubey{at}novell2.dept-med.pitt.edu

Abstract—The objective of this study was to characterize the effects of exogenous, drug-induced and cAMP-adenosine pathway–derived adenosine on collagen synthesis by and hypertrophy of vascular smooth muscle cells (SMCs). Confluent vascular SMCs were stimulated with 2.5% fetal calf serum in the presence and absence of adenosine receptor agonists [adenosine, 2-chloroadenosine, N6-cyclopentyladenosine, 5'-N-ethylcarboxamidoadenosine, 5'-N-methylcarboxamidoadenosine, and 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamino adenosine], drugs that increase levels of endogenous adenosine [erythro-9-(2-hydroxy-3-nonyl) adenine, dipyridamole, and iodotubericidin], and cAMP (increases adenosine by conversion to AMP and hence to adenosine via the cAMP-adenosine pathway). Adenosine receptor agonists inhibited fetal calf serum-induced collagen and total protein synthesis (as assessed by [3H]proline and [3H]leucine incorporation, respectively) with a relative potency profile consistent with the effects being mediated by adenosine A2B receptors. Erythro-9-(2-hydroxy-3-nonyl) adenine, dipyridamole, iodotubericidin, and cAMP also inhibited collagen and total protein synthesis. The effects of 2-chloroadenosine, erythro-9-(2-hydroxy-3-nonyl) adenine, iodotubericidin, and cAMP on collagen and total protein synthesis were attenuated by KF17837 and 1,3-dipropyl-8-p-sulfophenylxanthine (selective and nonselective A2 receptor antagonists, respectively) but not by 8-cyclopentyl-1,3-dipropylxanthine (selective A1 receptor antagonist). These studies indicate that exogenous, drug-induced and cAMP-adenosine pathway–derived adenosine inhibit vascular SMC collagen synthesis and hypertrophy via A2B receptors. Thus, exogenous A2B receptor agonists and drugs that modulate endogenous adenosine levels may protect against vasoocclusive disorders by attenuating extracellular matrix synthesis by and cellular hypertrophy of vascular SMCs. Moreover, the cAMP-adenosine pathway may protect against vascular hypertrophy.


Key Words: adenosine • muscle, smooth • extracellular matrix • collagen • hypertrophy




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
D. Yang, M. Koupenova, D. J. McCrann, K. J. Kopeikina, H. M. Kagan, B. M. Schreiber, and K. Ravid
The A2b adenosine receptor protects against vascular injury
PNAS, January 15, 2008; 105(2): 792 - 796.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
W. P. Robinson III, C. D. Douillet, P. M. Milano, R. C. Boucher, C. Patterson, and P. B. Rich
ATP stimulates MMP-2 release from human aortic smooth muscle cells via JNK signaling pathway
Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1988 - H1996.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. Shen, S. P. Halenda, M. Sturek, and P. A. Wilden
Novel Mitogenic Effect of Adenosine on Coronary Artery Smooth Muscle Cells: Role for the A1 Adenosine Receptor
Circ. Res., May 13, 2005; 96(9): 982 - 990.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Asbun, A. M. Manso, and F. J. Villarreal
Profibrotic influence of high glucose concentration on cardiac fibroblast functions: effects of losartan and vitamin E
Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H227 - H234.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. P. Headrick, B. Hack, and K. J. Ashton
Acute adenosinergic cardioprotection in ischemic-reperfused hearts
Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H1797 - H1818.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. P. Riksen, G. A. Rongen, H. J. Blom, F. G.M. Russel, G. H.J. Boers, and P. Smits
Potential role for adenosine in the pathogenesis of the vascular complications of hyperhomocysteinemia
Cardiovasc Res, August 1, 2003; 59(2): 271 - 276.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. S. Ostrom, J. E. Naugle, M. Hase, C. Gregorian, J. S. Swaney, P. A. Insel, L. L. Brunton, and J. G. Meszaros
Angiotensin II Enhances Adenylyl Cyclase Signaling via Ca2+/Calmodulin: Gq-Gs CROSS-TALK REGULATES COLLAGEN PRODUCTION IN CARDIAC FIBROBLASTS
J. Biol. Chem., June 27, 2003; 278(27): 24461 - 24468.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
B. Jian, J. Xu, J. Connolly, R. C. Savani, N. Narula, B. Liang, and R. J. Levy
Serotonin Mechanisms in Heart Valve Disease I: Serotonin-Induced Up-Regulation of Transforming Growth Factor-{beta}1 via G-Protein Signal Transduction in Aortic Valve Interstitial Cells
Am. J. Pathol., December 1, 2002; 161(6): 2111 - 2121.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
E. K. Jackson, C. Zhu, and S. P. Tofovic
Expression of adenosine receptors in the preglomerular microcirculation
Am J Physiol Renal Physiol, July 1, 2002; 283(1): F41 - F51.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. Burnstock
Purinergic Signaling and Vascular Cell Proliferation and Death
Arterioscler Thromb Vasc Biol, March 1, 2002; 22(3): 364 - 373.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
E. K. Jackson and R. K. Dubey
Role of the extracellular cAMP-adenosine pathway in renal physiology
Am J Physiol Renal Physiol, October 1, 2001; 281(4): F597 - F612.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. G. Webb, P. W. Yates, Q. Yang, Y. V. Mukhin, and S. M. Lanier
Adenylyl cyclase isoforms and signal integration in models of vascular smooth muscle cells
Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1545 - H1552.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. K. Dubey, D. G. Gillespie, Z. Mi, and E. K. Jackson
Endogenous Cyclic AMP-Adenosine Pathway Regulates Cardiac Fibroblast Growth
Hypertension, April 1, 2001; 37(4): 1095 - 1100.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. K. Jackson and Z. Mi
Preglomerular Microcirculation Expresses the cAMP-Adenosine Pathway
J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 23 - 28.
[Abstract] [Full Text]